Keros Therapeutics Crescita futura

Criteri Future verificati 0/6

Si prevede che i ricavi e gli utili di Keros Therapeutics diminuiranno rispettivamente del 23.2% e 35.4% all'anno, mentre si prevede che l'EPS diminuirà del 34% all'anno.

Informazioni chiave

-35.4%

Tasso di crescita degli utili

-34.05%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	22.8%
Tasso di crescita dei ricavi	-23.2%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	05 Jan 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Nov 18

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Aug 21

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

May 29

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

May 14

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

May 09

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:KROS - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	56	-150	-131	N/A	9
12/31/2027	15	-171	-135	N/A	9
12/31/2026	13	-146	-127	N/A	10
12/31/2025	246	82	82	N/A	10
9/30/2025	247	64	87	89	N/A
6/30/2025	233	19	53	55	N/A
3/31/2025	215	4	43	45	N/A
12/31/2024	4	-187	-163	-161	N/A
9/30/2024	1	-182	-143	-140	N/A
6/30/2024	0	-168	-146	-144	N/A
3/31/2024	0	-160	-137	-135	N/A
12/31/2023	0	-153	-127	-125	N/A
9/30/2023	0	-142	-123	-120	N/A
6/30/2023	N/A	-127	-113	-111	N/A
3/31/2023	N/A	-116	-105	-103	N/A
12/31/2022	N/A	-105	-71	-70	N/A
9/30/2022	20	-82	-69	-68	N/A
6/30/2022	20	-79	-59	-58	N/A
3/31/2022	20	-67	-54	-53	N/A
12/31/2021	20	-59	-63	-62	N/A
9/30/2021	0	-61	-51	-51	N/A
6/30/2021	0	-53	-48	-47	N/A
3/31/2021	N/A	-49	-40	-39	N/A
12/31/2020	N/A	-45	-37	-37	N/A
9/30/2020	3	-39	-35	-34	N/A
6/30/2020	5	-31	-27	-26	N/A
3/31/2020	8	-23	-22	-22	N/A
12/31/2019	10	-14	-16	-16	N/A
12/31/2018	10	-2	N/A	7	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di KROS diminuiranno nei prossimi 3 anni ( -35.4% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di KROS diminuiranno nei prossimi 3 anni ( -35.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di KROS diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che i ricavi di KROS diminuiranno nei prossimi 3 anni ( -23.2% all'anno).

Ricavi ad alta crescita: Si prevede che i ricavi di KROS diminuiranno nei prossimi 3 anni ( -23.2% all'anno).

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di KROS è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/01/23 08:21
Prezzo dell'azione a fine giornata	2026/01/23 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Keros Therapeutics, Inc. è coperta da 18 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Jason Zemansky	BofA Global Research
Corinne Johnson	Goldman Sachs
Andrew Fein	H.C. Wainwright & Co.

Keros Therapeutics Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 7.1% to US$88.11

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Consensus EPS estimates fall by 18%

Price target increased to US$98.75

Price target increased to US$94.00

Recent updates

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. (NasdaqGM:KROS) announces an Equity Buyback for 10,950,165 shares, representing 35.94% for $194.37 million.

Keros Therapeutics, Inc. Announces Board and Committee Changes, Effective October 15, 2025

Keros Therapeutics, Inc. Presents Additional Clinical Data from Its Ker-065 Program At the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

ADAR1 Sends Open Letter to Keros Board of Directors

Keros Therapeutics, Inc. Announces Management Changes, Effective August 18, 2025

Keros Therapeutics, Inc. Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Growth Index

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Keros Therapeutics, Inc. Announces Corporate Restructuring

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics, Inc., Annual General Meeting, Jun 04, 2025

Keros Therapeutics, Inc. Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock

Chief Scientific Officer exercised options and sold US$137k worth of stock

Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely